These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 377968)

  • 41. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Brenner P
    Contraception; 2006 Oct; 74(4):354; author reply 354-5. PubMed ID: 16982246
    [No Abstract]   [Full Text] [Related]  

  • 43. Three and one-half years' experience with a lower-dose combination oral contraceptive.
    Woutersz TB
    J Reprod Med; 1976 Jun; 16(6):338-44. PubMed ID: 957360
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Norgestimate: a clinical overview of a new progestin.
    Bringer J
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial.
    Kaunitz AM; Burkman RT; Fisher AC; LaGuardia KD
    Obstet Gynecol; 2009 Dec; 114(6):1205-1212. PubMed ID: 19935020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial.
    Schilling LH; Bolding OT; Chenault CB; Chong AP; Fleury F; Forrest K; Glick HI; Hasson HM; Heil CG; London RS
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1264-8. PubMed ID: 2655451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.
    German P; Moorehead L; Pang P; Vimal M; Mathias A
    J Clin Pharmacol; 2014 Nov; 54(11):1290-8. PubMed ID: 24925712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
    Olson WH; Lippman JS; Robisch DM
    Int J Fertil Womens Med; 1998; 43(6):286-90. PubMed ID: 9920537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Low dose p-pills, Gynatrol and Mikrogyn].
    Falck Larsen J
    Ugeskr Laeger; 1976 Sep; 138(40):2446-7. PubMed ID: 969002
    [No Abstract]   [Full Text] [Related]  

  • 51. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study.
    Carlborg L
    Acta Obstet Gynecol Scand Suppl; 1986; 134():29-32. PubMed ID: 2949481
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
    Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S
    Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A low-dose combination oral contraceptive. Experience with 1,700 women treated for 22,489 cycles.
    Woutersz TB
    J Reprod Med; 1981 Dec; 26(12):615-20. PubMed ID: 7033528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ovarian function during treatment with high ratio levonorgestrel/ethinyl estradiol as oral contraceptives.
    Johansson ED; Elamsson K; Elmestedt U
    Gynecol Obstet Invest; 1982; 14(2):97-105. PubMed ID: 6811379
    [No Abstract]   [Full Text] [Related]  

  • 55. Control of fertility with oral medication.
    Diddle AW; Watts GF; Gardner WH; Williamson PJ
    West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical assessment of a low-oestrogen combined oral contraceptive.
    Bye PG; Elstein M
    Br Med J; 1973 May; 2(5863):389-92. PubMed ID: 4574044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical experience with ethinyl estradiol and d-norgestrel as an oral contraceptive.
    Apelo R; Veloso I
    Fertil Steril; 1975 Mar; 26(3):283-8. PubMed ID: 1116622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
    Kaunitz AM; Archer DF; Mishell DR; Foegh M
    Am J Obstet Gynecol; 2015 Mar; 212(3):318.e1-8. PubMed ID: 25220709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral contraceptives according to the normophasic principle.
    Borglin NE; Klottrup P
    Arzneimittelforschung; 1978; 28(12):2354-7. PubMed ID: 582954
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A double-blind comparison of two oral contraceptives containing 50 mu g. and 30 mu g. ethinyl estradiol.
    Dionne P; Vickerson F
    Curr Ther Res Clin Exp; 1974 Apr; 16(4):281-8. PubMed ID: 4208342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.